moclobemide has been researched along with Schizophrenia in 5 studies
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.
moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to describe preliminary experience with moclobemide in the treatment of depressive disorders in the University outpatient clinic in Malaysia." | 9.08 | Preliminary experience with moclobemide for the treatment of depressive disorders in Malaysia. ( Indran, SK, 1995) |
| "The cognitive effects of nicotine in humans remain a topic of great interest, due to the continued prevalence of cigarette smoking in society as well as the hypothesis that cognitively impaired populations such as schizophrenia patients use nicotine as a means of self-medicating against deficits of sensory gating." | 5.20 | The separate and combined effects of monoamine oxidase inhibition and nicotine on P50 sensory gating. ( Blier, P; Fisher, D; Illivitsky, V; Knott, V; Smith, DM, 2015) |
| "The study was designed as a 6-week, two-center, fixed-dose, comparison study of 400 mg/day of amisulpride versus 300 mg/day of moclobemide as an adjunctive treatment in 53 schizophrenia and schizoaffective disorder patients (diagnosed according to DSM-IV) suffering from CIS." | 5.15 | Amisulpride versus moclobemide in treatment of clozapine-induced hypersalivation. ( Bergman, J; Kreinin, A; Lerner, V; Libov, I; Miodownik, C; Shestakova, D; Sokolik, S, 2011) |
| "The objective of this study was to describe preliminary experience with moclobemide in the treatment of depressive disorders in the University outpatient clinic in Malaysia." | 5.08 | Preliminary experience with moclobemide for the treatment of depressive disorders in Malaysia. ( Indran, SK, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Smith, DM | 1 |
| Fisher, D | 1 |
| Blier, P | 1 |
| Illivitsky, V | 1 |
| Knott, V | 1 |
| Kreinin, A | 1 |
| Miodownik, C | 1 |
| Sokolik, S | 1 |
| Shestakova, D | 1 |
| Libov, I | 1 |
| Bergman, J | 1 |
| Lerner, V | 1 |
| Taylor, D | 1 |
| Reveley, A | 1 |
| Faivre, F | 1 |
| Indran, SK | 1 |
| Silver, H | 1 |
| Aharon, N | 1 |
| Hausfater, N | 1 |
| Jahjah, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Benzamide Derivates (Amisulpride, Moclobemide and Tiapride) as Treatment of Clozapine-induced Hypersalivation: Pilot Double Phase Study: Open and Double-blind[NCT00534573] | Phase 3 | 54 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for moclobemide and Schizophrenia
| Article | Year |
|---|---|
The separate and combined effects of monoamine oxidase inhibition and nicotine on P50 sensory gating.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Evoked Potentials; Female; Humans; Male; Moclobemide | 2015 |
Amisulpride versus moclobemide in treatment of clozapine-induced hypersalivation.
Topics: Adult; Aged; Amisulpride; Antipsychotic Agents; Clozapine; Cross-Over Studies; Female; Humans; Male; | 2011 |
Preliminary experience with moclobemide for the treatment of depressive disorders in Malaysia.
Topics: Adult; Antidepressive Agents; Benzamides; Depressive Disorder; Dizziness; Female; Follow-Up Studies; | 1995 |
The effect of augmentation with moclobemide on symptoms of schizophrenia.
Topics: Antipsychotic Agents; Benzamides; Drug Synergism; Female; Humans; Male; Middle Aged; Moclobemide; Mo | 1999 |
1 other study available for moclobemide and Schizophrenia
| Article | Year |
|---|---|
Clozapine-induced hypotension treated with moclobemide and Bovril.
Topics: Adult; Antipsychotic Agents; Benzamides; Clozapine; Dose-Response Relationship, Drug; Drug Administr | 1995 |